Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents-Reference-Cited by-同舟云学术

Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents

Published:2024-09-05 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fang Yingsi¹^ORCID,Clarke Lloyd G.¹²,Smith Brandon J.²³,Shah Sunish¹²^ORCID

Affiliation:

1. Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

2. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

3. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Abstract

ABSTRACT This study investigated the real-world incidence rate of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents. A retrospective cohort of 479 adult patients was assessed between January 2015 and July 2023. Overall, a rare rate of 0.4% (2/479) of possible serotonin syndrome with tedizolid was identified. Given that concomitant serotonergic agents were commonly used, further study is warranted to determine causality.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00870-24

Reference18 articles.

1. In Vitro , In Vivo , and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions

2. Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

3. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

4. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice

5. Switching and stopping antidepressants